Pre-order Enquiry
Download Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Market Analysis and Insights: Global Radiopharmaceutical Market
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
Due to the COVID-19 pandemic, the global Radiopharmaceutical market size is estimated to be worth US$ 6761 million in 2022 and is forecast to a readjusted size of US$ 11660 million by 2029 with a CAGR of 8.0% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Actinium-225 accounting for % of the Radiopharmaceutical global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Oncology segment is altered to an % CAGR throughout this forecast period.
The global Radiopharmaceutical top three manufacturers include the Bracco Imaging, Bayer and Mallinckrodt, with about 47% market shares. North America and Europe is the main consumption places, with a consumption market share nearly 45% and 27%.
Global Radiopharmaceutical Scope and Market Size
The global Radiopharmaceutical market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Radiopharmaceutical market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other
Segment by Application
Oncology
Cardiology
Other
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
Due to the COVID-19 pandemic, the global Radiopharmaceutical market size is estimated to be worth US$ 6761 million in 2022 and is forecast to a readjusted size of US$ 11660 million by 2029 with a CAGR of 8.0% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Actinium-225 accounting for % of the Radiopharmaceutical global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Oncology segment is altered to an % CAGR throughout this forecast period.
The global Radiopharmaceutical top three manufacturers include the Bracco Imaging, Bayer and Mallinckrodt, with about 47% market shares. North America and Europe is the main consumption places, with a consumption market share nearly 45% and 27%.
Global Radiopharmaceutical Scope and Market Size
The global Radiopharmaceutical market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Radiopharmaceutical market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other
Segment by Application
Oncology
Cardiology
Other
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
Frequently Asked Questions
This market study covers the global and regional market with an
in-depth analysis of the
overall growth prospects...
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by
highlighting information on
different aspects including drivers, restraints...
